TABLE 3.
Performance of the eight laboratory assays in the prediction of CMV disease according to pretransplantation serological status
| Patient group and test | Prediction of CMV diseasea
|
Mean time from positive result to disease onset (days)b | Proportion of positive tests occurring before disease onseta | |||
|---|---|---|---|---|---|---|
| Sensitivity | Specificity | PPV | NPV | |||
| Seronegative recipients | ||||||
| DAT | 1/8 (13) | 5/5 (100) | 1/1 (100) | 5/12 (42) | +4.1 | 1/8 (13) |
| CMVG | 2/8 (25) | 5/5 (100) | 2/2 (100) | 5/11 (46) | +4.1 | 2/8 (25) |
| CMVM | 2/8 (25) | 5/5 (100) | 2/2 (100) | 5/11 (46) | +9.1 | 2/8 (25) |
| HCS | 4/8 (50) | 5/5 (100) | 4/4 (100) | 5/9 (56) | +1.4 | 4/7 (57) |
| P-PCR | 4/8 (50) | 5/5 (100) | 4/4 (100) | 5/9 (56) | −6.3 | 4/7 (57) |
| P-AMP | 5/8 (63) | 5/5 (100) | 5/5 (100) | 5/8 (63) | −2.4 | 5/7 (72) |
| L-PCR | 7/8 (88) | 5/5 (100) | 7/7 (100) | 5/6 (83) | −8.0 | 7/8 (88) |
| L-AMP | 6/8 (75) | 5/5 (100) | 6/6 (100) | 5/7 (71) | −13.4 | 6/8 (75) |
| Seropositive recipients | ||||||
| DAT | 0/5 (0) | 17/19 (90) | 0/2 (0) | 17/22 (77) | +7.0 | 0/3 (0) |
| CMVG | 0/5 (0) | 13/19 (68) | 0/6 (0)c | 13/18 (72) | +10.5 | 0/2 (0) |
| CMVM | 0/5 (0) | 17/19 (90) | 0/2 (0) | 17/22 (77) | +7.5 | 0/2 (0) |
| HCS | 2/5 (40) | 14/19 (74) | 2/7 (29) | 14/17 (82) | −2.0 | 2/4 (50) |
| P-PCR | 3/5 (60) | 10/19 (53) | 3/12 (25)c | 10/12 (83) | −10.8 | 3/4 (75) |
| P-AMP | 3/5 (60) | 14/19 (74) | 3/8 (38)c | 14/16 (88) | −5.5 | 3/4 (75) |
| L-PCR | 2/5 (40) | 11/19 (58) | 2/10 (20)c | 11/14 (79) | +1.8 | 2/4 (50) |
| L-AMP | 3/5 (60) | 11/19 (58) | 3/11 (27)c | 11/13 (85) | −6.8 | 3/5 (40) |
a
Data represent number of patients positive/total number of patients (percent).
b
Time of CMV disease is time zero. +, positive test result after onset of illness; −, positive test result before onset of illness.
c
Significant difference (P < 0.05) between R− and R+ groups by two-tailed Fisher’s exact test.